Related:Supplements Blamed for Liver Toxicity
11/6/2013
WASHINGTON -- The rate of liver damage caused by dietary and herbal supplements -- especially those used for bodybuilding -- appears to be on the rise, a researcher said here.
more
Hepatotoxicity from herbal, dietary supplements rising
Source - Healio
Researchers evaluated data collected from the Drug Induced Liver Injury Network (DILIN) on 845 patients who either probably, very likely or definitely experienced liver injury as a result of the suspected agent in each case.
Two hundred sixty-two herbal dietary supplements (HDS) were used by 136 patients with HDS-induced liver injury (HILI). After excluding seven patients who used a combination of HDS, the evaluated cohort included 44 patients who used HDS for bodybuilding, 85 who used HDS products marketed for other purposes, and 709 who experienced drug-induced liver injury (DILI).
WASHINGTON — Liver injury attributable to the use of herbal and dietary supplements, particularly products marketed for bodybuilding, has increased in recent years, according to data presented at The Liver Meeting.
Bodybuilding HDS users were more frequently men and had significantly fewer comorbidities than either users of other HDS or prescription drug users (P<.001). Total serum bilirubin levels at the onset of injury were greater among these patients (median 9.8 mg/dL) than for users of other HDS products (7.9 mg/dL) or prescription drug users (4.3 mg/dL; P<.001). Patients who used bodybuilding HDS also had lower ALT at DILIN entry (173 IU/L vs. 1,019 IU/L for other HDS and 505 IU/L for prescription drugs; P<.001).
No patients with HILI related to bodybuilding HDS required liver transplantation, compared with 13% of other HDS users and 3% of prescription drug users (P<.001). Hospitalization tended to be more frequent in the bodybuilding group (P=.08). No patients using bodybuilding HDS died, compared with 4% of other HDS users and 7% of prescription drug users (P=.098).
The percentage of liver injuries related to HDS products increased from 7% of cases between 2004 and 2005 to 20% between 2010 and 2012 (P<.001). This trend was significant both for cases attributable to bodybuilding products (P=.01) and for all other HDS products (P=.05).
“This was not a population-based study, so additional efforts to characterize the true burden of disease in the US population are needed, and in fact are being undertaken by the DILIN,” researcher Victor J. Navarro,MD, of the hepatology division at Einstein Medical Center, said. “Liver injury resulting from nonbodybuilding HDS may be more severe than that which results from prescription drugs, as evidenced by the higher transplantation rate. And, contrary to common belief, not all HDS are safe; certainly not [with regard to] the capacity to cause harm to the liver.”
Disclosure: Navarro reports no relevant financial disclosures.
For more information:
Navarro VJ. #113: Presidential Plenary: Transitional Advances in Hepatology: The Rising Burden of Herbal and Dietary Supplement Induced Hepatotoxicity in the USA. Presented at: The Liver Meeting 2013; Nov. 1-5, Washington.
Complete AASLD Coverage
Commentary/Abstracts and Videos @ Healio
Additional headlines from The Liver Meeting 2013
ED screening identifies previously undiagnosed patients with HCV
November 5, 2013
Meeting News Coverage
Medication trade-offs significantly associated with readmissions after liver transplant
November 5, 2013
Meeting News Coverage
No benefit from post-HPE corticosteroid therapy in infants with biliary atresia
November 4, 2013
Meeting News Coverage
Hepatotoxicity from herbal, dietary supplements rising
November 4, 2013
Meeting News CoverageVideo
3-D liver reproduction offers new planning, educational opportunities
November 4, 2013
Meeting News Coverage
Longer transplant waits for HCC patients may be beneficial
November 4, 2013
Meeting News CoverageVideo
Cell-based assay may predict liver transplant rejection in children
November 3, 2013
Meeting News Coverage
Accuracy, reproducibility of liver disease assessment poor in morbidly obese patients
November 3, 2013
Meeting News Coverage
Liver Meeting speaker: HCC exceptions contributing to MELD inflation, transplant inequity
November 3, 2013
Meeting News Coverage
Bleeding complications predict, but don’t cause poor outcomes in patients with acute liver failure
November 2, 2013
This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Subscribe to:
Post Comments (Atom)
FDA spokeswoman Shelly Burgess said that, in spite of regulation, many companies are ignoring the rules anyway. “We are seeing a very high percentage — approximately 70 percent.
ReplyDeleteherbal supplement